Back to top
more

Neurocrine Biosciences (NBIX)

(Delayed Data from NSDQ)

$138.48 USD

138.48
637,476

+2.33 (1.71%)

Updated May 14, 2024 04:00 PM ET

After-Market: $138.32 -0.16 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

COLL or NBIX: Which Is the Better Value Stock Right Now?

COLL vs. NBIX: Which Stock Is the Better Value Option?

COLL or NBIX: Which Is the Better Value Stock Right Now?

COLL vs. NBIX: Which Stock Is the Better Value Option?

Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.32% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group

The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group

Nalak Das headshot

5 Top Stocks Set to Beat Earnings Estimates Next Week

Although, expectations for fourth-quarter 2019 earnings are negative at present, results so far are far better than initially anticipated.

Sanghamitra Saha headshot

Bet on Earnings Beat With 5 Top-Ranked Stocks

These top-ranked stocks are likely to beat on bottom line in their next releases.

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta

Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta

Sanghamitra Saha headshot

Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

AMRX vs. NBIX: Which Stock Is the Better Value Option?

AMRX vs. NBIX: Which Stock Is the Better Value Option?

Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?

Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Christopher Vargas headshot

3 Breakout Stocks of the Last Decade to Consider for 2020

The 2010s were a fruitful decade for investors as the S&P 500 has surged over 189% so far.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Sweta Killa headshot

Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4

Investors could be well served by ETFs and stocks from sectors that house top-ranked industries.

Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CTLT or NBIX: Which Is the Better Value Stock Right Now?

CTLT vs. NBIX: Which Stock Is the Better Value Option?

Kinjel Shah headshot

Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?

HKMPF vs. NBIX: Which Stock Is the Better Value Option?

Lannett (LCI) Hits 52-Week High, Can the Run Continue?

Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Neurocrine Biosciences (NBIX) a Great Growth Stock?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Neurocrine Biosciences (NBIX).